Drug Type Monoclonal antibody |
Synonyms Adalimumab (Genetical Recombination), Raheara, ABT-D2E7 + [7] |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (31 Dec 2002), |
RegulationPriority Review (CN), Overseas New Drugs Urgently Needed in Clinical Settings (CN) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02597 | Adalimumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pyoderma Gangrenosum | JP | 27 Nov 2020 | |
Pustular psoriasis | JP | 23 Mar 2018 | |
Behcet Syndrome | JP | 17 Jun 2016 | |
Psoriasis vulgaris | JP | 17 Jun 2016 | |
Colitis, Ulcerative | AU | 10 Dec 2003 | |
Enthesitis-Related Arthritis | AU | 10 Dec 2003 | |
Hidradenitis Suppurativa | AU | 10 Dec 2003 | |
Polyarticular Juvenile Idiopathic Arthritis | AU | 10 Dec 2003 | |
Psoriasis | AU | 10 Dec 2003 | |
Juvenile Arthritis | EU | 08 Sep 2003 | |
Juvenile Arthritis | IS | 08 Sep 2003 | |
Juvenile Arthritis | LI | 08 Sep 2003 | |
Juvenile Arthritis | NO | 08 Sep 2003 | |
Pediatric Crohn's Disease | EU | 08 Sep 2003 | |
Pediatric Crohn's Disease | IS | 08 Sep 2003 | |
Pediatric Crohn's Disease | LI | 08 Sep 2003 | |
Pediatric Crohn's Disease | NO | 08 Sep 2003 | |
Plaque psoriasis | EU | 08 Sep 2003 | |
Plaque psoriasis | IS | 08 Sep 2003 | |
Plaque psoriasis | LI | 08 Sep 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Generalized Pustular Psoriasis | Phase 3 | - | 28 Sep 2015 | |
Oral Ulcer | Phase 3 | US | 01 May 2014 | |
Oral Ulcer | Phase 3 | AT | 01 May 2014 | |
Oral Ulcer | Phase 3 | BE | 01 May 2014 | |
Oral Ulcer | Phase 3 | CA | 01 May 2014 | |
Oral Ulcer | Phase 3 | CZ | 01 May 2014 | |
Oral Ulcer | Phase 3 | DK | 01 May 2014 | |
Oral Ulcer | Phase 3 | FR | 01 May 2014 | |
Oral Ulcer | Phase 3 | DE | 01 May 2014 | |
Oral Ulcer | Phase 3 | HU | 01 May 2014 |
Phase 4 | 32 | Lab Work (DMARD's Responder and Non-Responder) | ekoiyinvlt(gklmnulxww) = jrpehcxqvg fwudmsdshl (fkjqzaxyav, mpocbmxxrg - kfcjjvoynr) View more | - | 10 Jul 2024 | ||
Naproxen+Medrol+Hydroxychloroquine+humira+Prednisone+Lab Work+Triamcinolone+Sulfasalazine+Certolizumab pegol (CDP870, tradename Cimzia)+Methotrexate+Leflunomide (DMARD's Plus Cimzia (Certolizumab Pegol)) | fjdfqyxhvb(ogfxdtjmwo) = ddamzpmsau yezhdbnuqw (rmwztqtokh, vokkzgasch - qxoitktdfm) View more | ||||||
Not Applicable | - | Tapering ADL first | onsxapmvfe(ehhmxiimzb) = ncgaedwyqt tnkuiokpuk (gmlnrmezeh ) | - | 13 Nov 2023 | ||
Not Applicable | - | afjfzdrtxw(zpmlocciiq) = A near-complete response was achieved without adverse events (AEs) for the last 6 months mzofmxvwlw (hywtqlmotl ) | - | 11 Oct 2023 | |||
Not Applicable | 51 | nxjikkzveo(bmmsppaljo) = cctyhzmhhf dnigqqaulf (wafimvgspk ) View more | - | 11 Oct 2023 | |||
nxjikkzveo(bmmsppaljo) = lbigtznyix dnigqqaulf (wafimvgspk ) View more | |||||||
Not Applicable | Hidradenitis Suppurativa TNF-alpha inhibitor Adalimumab | 56 | Adalimumab 40mg weekly | eptymuuucq(mndlujwbyf) = rnlsgkbrok nphoorwiys (cdandwhbnq ) | Negative | 11 Oct 2023 | |
Not Applicable | 37 | awroseatsy(zrxdrldwis) = 5 patients discontinued treatment due to severe injection site pain uposwzpgzt (dpnzxexowx ) View more | - | 03 Jul 2023 | |||
Not Applicable | 15 | zjgisxtodh(kymqrpkkoe) = ldgyglyaco yynbuovebz (jgamvdadns ) View more | Positive | 01 Jun 2023 | |||
Phase 3 | Charlson Comorbidity Index | 1,402 | bsmsecnvie(vgbeazuafh) = bbirxlsgvy qgpyebvglb (xeohsascbz ) View more | - | 31 May 2023 | ||
Adalimumab | bsmsecnvie(vgbeazuafh) = ukkcaqpayt qgpyebvglb (xeohsascbz ) View more | ||||||
Not Applicable | 378 | Originator Adalimumab (Humira) | byzwzdgiue(svtuthwrcb) = ficfzvifov ztyiumncen (eacgvardyu ) View more | - | 31 May 2023 | ||
Biosimilar Adalimumab (Hyrimoz) | byzwzdgiue(svtuthwrcb) = ryjobqadoh ztyiumncen (eacgvardyu ) View more | ||||||
Not Applicable | - | Adalimumab (ADA) | ejwqyshqjs(gvytewadny) = Adverse event incidence was comparable between the two groups (ADA vs. TCZ: 38.10% vs. 47.37%) yghgxzymmd (ierondclmu ) | Positive | 31 May 2023 | ||
Tocilizumab (TCZ) |